SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

X4 Pharmaceuticals Presents Phase 3 Trial Plans for Mavorixafor

X4 Pharmaceuticals presented plans for a Phase 3 trial of mavorixafor in primary chronic neutropenia.

XFOR

Related stories